Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2018
- Pages: 601
- Published: July 2018
- Report Code: GMDHC10612IDB
Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2018’, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH)
– The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Non-Alcoholic Steatohepatitis (NASH) therapeutics and enlists all their major and minor projects
– The report assesses Non-Alcoholic Steatohepatitis (NASH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abide Therapeutics Inc
AdAlta Ltd
Akcea Therapeutics Inc
Albireo Pharma Inc
Aldeyra Therapeutics Inc
Allergan Plc
Araim Pharmaceuticals Inc
Arcturus Therapeutics Ltd
Ardelyx Inc
Ascletis Inc
Assembly Biosciences Inc
AstraZeneca Plc
Baliopharm AG
Betagenon AB
BioElectron Technology Corp
Bird Rock Bio Inc
BLR Bio LLC
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Cardax Inc
Carmot Therapeutics Inc
Catabasis Pharmaceuticals Inc
Celgene Corp
Cerenis Therapeutics Holding SA
ChemoCentryx Inc
CJ HealthCare Corp
CohBar Inc
ConSynance Therapeutics Inc
CymaBay Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Dicerna Pharmaceuticals Inc
Dimerix Bioscience Pty Ltd
Dong-A Socio Holdings Co Ltd
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperion Therapeutics Inc
Exicure Inc
Forma Therapeutics Inc
Galectin Therapeutics Inc
Galecto Biotech AB
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GRI Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoShear Therapeutics, LLC
IB Pharmaceuticals Inc
iCo Therapeutics Inc
Immupharma Plc
Immuron Ltd
Integral Molecular Inc
Intercept Pharmaceuticals Inc
Inventiva
Ionis Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
Kyorin Pharmaceutical Co Ltd
Madrigal Pharmaceuticals Inc
MallInckrodt Plc
MedImmune LLC
Merck & Co Inc
Metabolys SAS
Metacrine Inc
Mina Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
Naia Ltd
NeuroVive Pharmaceutical AB
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
NorthSea Therapeutics BV
Novartis AG
NovaTarg Therapeutics Inc
Novo Nordisk AS
Nuevolution AB
NuSirt Biopharma Inc
Oramed Pharmaceuticals Inc
Pfizer Inc
Pharmaxis Ltd
Poxel SA
Promethera Biosciences SA
ProMetic Life Sciences Inc
Protalix BioTherapeutics Inc
Redx Pharma Plc
Regulus Therapeutics Inc
reMYND NV
Ritter Pharmaceuticals Inc
Saje Pharma LLC
Sancilio & Company Inc
Sanofi
ScandiCure AB
Second Genome Inc
Seres Therapeutics Inc
Shire Plc
Sprint Bioscience AB
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Terns Pharmaceuticals Inc
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
Vascular Biogenics Ltd
Verlyx Pharma Inc
Viking Therapeutics Inc
Visionary Pharmaceuticals Inc
WAVE Life Sciences Ltd
Zafgen Inc
Zebra Discovery Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.